

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Inflazyme Pharmaceuticals Ltd.	11/16/2007
RECEIVING PARTY DATA	
Name:	Biolipox AB
Street Address:	Berzelius vag 3
Internal Address:	plan 5
City:	Solna
State/Country:	SWEDEN
Postal Code:	S-171 65
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	6770658
CORRESPONDENCE DATA	
Fax Number:	(206)682-6031
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	2066224900
Email:	carolw@seedip.com
Correspondent Name:	Carol J. Roth
Address Line 1:	701 Fifth Avenue
Address Line 2:	Suite 5400
Address Line 4:	Seattle, WASHINGTON 98104-7092
ATTORNEY DOCKET NUMBER:	310151.403USC1
NAME OF SUBMITTER:	Carol J. Roth
Total Attachments: 8 source=310151.403USC1#page1.tif source=310151.403USC1#page2.tif	

CH 6770658 \$40.00

500479127

PATENT
REEL: 020599 FRAME: 0251

source=310151.403USC1#page3.tif
source=310151.403USC1#page4.tif
source=310151.403USC1#page5.tif
source=310151.403USC1#page6.tif
source=310151.403USC1#page7.tif
source=310151.403USC1#page8.tif

ASSIGNMENT

WHEREAS, Inflazyme Pharmaceuticals Ltd. (hereinafter referred to as ASSIGNOR), a corporation of Canada having a place of business at 5600 Parkwood Way, Suite 425, Richmond, British Columbia, Canada V6V 2M2, is the sole and exclusive owner of the entire right, title and interest in and to all of the patent applications and patents listed in Exhibit A;

WHEREAS, Biolipox AB (hereinafter referred to as ASSIGNEE), a corporation of Sweden having a place of business at Berzelius väg 3, plan 5, S-171 65 Solna, Sweden, is desirous of acquiring the entire right, title and interest in and to the aforementioned patents and patent applications;

NOW, THEREFORE, in consideration of the sum of One Canadian Dollar (\$1.00) paid to ASSIGNOR in hand, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR does hereby sell, assign and transfer unto said ASSIGNEE, its entire right, title and interest in and to the patent applications and patents listed in Exhibit A, and any and all patents issuing from any patent application listed in Exhibit A, and any and all continuations, divisions, reissues, supplemental protection certificates, or extensions of any such patents and applications listed in Exhibit A (collectively, the "Assigned Patents"), and the inventions and discoveries set forth therein, and ASSIGNOR's right to file applications on such inventions and discoveries, to be held and enjoyed by the ASSIGNEE, for its own use and behalf and the use and behalf of its successors and assigns, to the full end of the term or terms for which such patents may be granted as fully and entirely as the same would have been held and enjoyed by the ASSIGNOR had this sale and assignment not been made, and ASSIGNOR hereby authorizes and requests any official of any country whose duty it is to issue patents, to issue or transfer all Assigned Patents to ASSIGNEE, its successors and assigns, in accordance with the terms of the assignment, or otherwise as ASSIGNEE may direct.

This Assignment is binding on ASSIGNOR, its successors and assigns, and will inure to the benefit of the ASSIGNEE, its successors and assigns. Nothing in this instrument, express or implied, is intended or shall be construed to confer upon, or give to, any person, corporation or entity other than ASSIGNEE, its successors and assigns, any remedy or claim

PDE4

under or by reason of this instrument, or any terms, covenants or conditions hereof, and all the terms, covenants and conditions in this instrument shall be for the sole and exclusive benefit of ASSIGNEE and its successors and assigns.

This Assignment is effective as of November 16, 2007.

INFLAZONE PHARMACEUTICALS LTD. (ASSIGNOR)

By: [Signature]

Print Name Michael Leggett

Title: Chief Financial Officer

Date: November 16, 2007

Province of British Columbia

Country of Canada

} ss.

I certify that I know or have satisfactory evidence that Michael Leggett is the person who appeared before me, and said person acknowledged that he signed this instrument and acknowledged it to be his free and voluntary act for the uses and purposes mentioned in the instrument.

Dated Nov. 16, 2007

Signature of
Notary Public

[Signature]

Printed Name

CATHERINE E. WADE
HEENAN BLAIKIE LLP
#2200 - 1055 West Hastings Street
Vancouver, BC V6E 2E9
T: 604-891-1155 Fax: 1-866-598-8011

PDE4.

BIOLPOX (ASSIGNEE)

By: [Signature]

Print Name Torbjörn Bjerke

Title: President & CEO

Date: 2007-11-15

)
) ss.

I certify that I know or have satisfactory evidence that _____ is the
person who appeared before me, and said person acknowledged that he signed this instrument and
acknowledged it to be his free and voluntary act for the uses and purposes mentioned in the instrument.

Dated _____

Signature of
Notary Public _____

Printed Name _____

This is to certify that
Mr Torbjörn Bjerke ---
has signed his name above.

Stockholm, November 26, 2007

Ex officio:

[Signature]
Notary Public



PDE4

EXHIBIT A
PDE4 INHIBITOR PATENTS AND PATENT APPLICATIONS

Inflazyme Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications

REDACTED

PDE4

Inflazyme Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
480117.403USC1 Non-provisional United States Inflazyme Pharmaceuticals Ltd.	SUBSTITUTED γ -PHENYL- A-LACTAMS AND USES RELATED THERETO	10/263,336 6,770,658	10/01/2002 08/03/2004 09/09/2019	09/786,949 filed 05/11/01 PCT/CA99/00819 filed 09/09/1999 60/099,637 filed 09/09/1998 60/121,507 filed 02/23/99 60/149,517 filed 08/17/99 This application is also a CIP of USAN 10/081,993, filed 02/22/02 (403C2).

REDACTED

PDE4

Inflazyme Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
---	-------	-------------------------	--	--------------------------

REDACTED

PDE4

Inflazyme Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
---	-------	-------------------------	--	--------------------------

REDACTED

PDE4

Inflazyme Reference No. Application Type Country	Title	Appl. No. Patent No.	Appl. Date Issue Date Expiration Date	Priority Applications
---	-------	-------------------------	--	--------------------------

REDACTED